

Gastro-oesophageal reflux disease in primary care

European Journal of Gastroenterology and Hepatology
10, 119-124

DOI: 10.1097/00042737-199802000-00004

Citation Report

#	ARTICLE	IF	CITATIONS
1	What's new in pathology, pathophysiology and management of benign esophageal disorders?. Ecological Management and Restoration, 1997, 10, 282-302.	0.2	1
2	1 Nomenclature of dyspepsia, dyspepsia subgroups and functional dyspepsia: Clarifying the concepts. Bailliere's Clinical Gastroenterology, 1998, 12, 417-433.	0.9	41
3	11 Treatment of functional dyspepsia. Bailliere's Clinical Gastroenterology, 1998, 12, 573-586.	0.9	5
4	Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Alimentary Pharmacology and Therapeutics, 1998, 12, 1055-1065.	1.9	333
5	The Usefulness of a Structured Questionnaire in the Assessment of Symptomatic Gastroesophageal Reflux Disease. Scandinavian Journal of Gastroenterology, 1998, 33, 1023-1029.	0.6	416
6	Proton Pump Inhibitors. Drugs, 1998, 56, 307-335.	4.9	219
7	Omeprazole. Drugs, 1998, 56, 447-486.	4.9	88
8	Gastro-Oesophageal Reflux Disease. Digestion, 1998, 59, 433-445.	1.2	113
9	Original Paper: Gastro-oesophageal reflux disease in primary care Comparison and evaluation of existing national guidelines and development of uniform European guidelines. European Journal of General Practice, 1999, 5, 88-97.	0.9	20
10	Heartburn treatment in primary care: randomised, double blind study for 8 weeks. BMJ: British Medical Journal, 1999, 319, 550-553.	2.4	100
12	On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis-a placebo-controlled randomized trial. Alimentary Pharmacology and Therapeutics, 1999, 13, 907-914.	1.9	182
13	Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 1999, 13, 1621-1630.	1.9	82
14	What's new in the pathology, pathophysiology and management of benign esophageal disorders?. Ecological Management and Restoration, 1999, 12, 219-237.	0.2	5
15	Patients with Functional Dyspepsia Responding to Omeprazole Have a Characteristic Gastro-oesophageal Reflux Pattern. Scandinavian Journal of Gastroenterology, 1999, 34, 575-579.	0.6	56
16	Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut, 1999, 45, 172-180.	6.1	1,959
17	ENDOSCOPY-NEGATIVE GASTROESOPHAGEAL REFLUX DISEASE. Gastroenterology Clinics of North America, 1999, 28, 893-904.	1.0	27
18	DIAGNOSTIC EVALUATION IN GASTROESOPHAGEAL REFLUX DISEASE. Gastroenterology Clinics of North America, 1999, 28, 809-830.	1.0	28
19	Relative Efficacies of Gastric Proton Pump Inhibitors: Their Clinical and Pharmacological Basis. Pharmacology, 1999, 59, 57-77.	0.9	49

#	ARTICLE	IF	CITATIONS
20	Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. <i>Alimentary Pharmacology and Therapeutics</i> , 2000, 14, 1249-1258.	1.9	320
21	Epidemiology and natural history of reflux disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 743-757.	1.0	58
22	Strategies for medical management of reflux disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 775-791.	1.0	12
23	Endoscopy-negative reflux disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 827-837.	1.0	25
24	Functional gastroesophageal reflux disease (GERD). <i>Current Treatment Options in Gastroenterology</i> , 2000, 3, 295-302.	0.3	6
25	Pathophysiology of gastro-oesophageal reflux: recent advances and therapeutic implications. <i>Digestive and Liver Disease</i> , 2000, 32, 235-238.	0.4	1
26	Diagnosing gastro-oesophageal reflux: endoscopy, pH-metry or empirical trial?. <i>Digestive and Liver Disease</i> , 2000, 32, 239-241.	0.4	1
27	Extraesophageal presentations of gastroesophageal reflux disease: an overview. <i>American Journal of Gastroenterology</i> , 2000, 95, S1-S3.	0.2	59
28	Improving opportunities for effective management of gastro-oesophageal reflux disease. <i>Digestive and Liver Disease</i> , 2001, 33, 720-730.	0.4	5
29	Non-erosive reflux disease: the real problem in gastro-oesophageal reflux disease. <i>Digestive and Liver Disease</i> , 2001, 33, 523-527.	0.4	45
30	Esomeprazole 40mg Capsules are Bioequivalent when Administered Intact or as the Contents Mixed with Applesauce*. <i>Clinical Drug Investigation</i> , 2001, 21, 67-71.	1.1	12
31	Nonerosive reflux disease—current concepts and dilemmas. <i>American Journal of Gastroenterology</i> , 2001, 96, 303-314.	0.2	19
32	Quality of life in patients with gastroesophageal reflux disease. <i>American Journal of Gastroenterology</i> , 2001, 96, S46-S53.	0.2	62
33	Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2849-2857.	0.2	3
34	Symptom and Health-Related Quality-of-Life Measures for Use in Selected Gastrointestinal Disease Studies. <i>Pharmacoeconomics</i> , 2001, 19, 349-363.	1.7	43
35	Endoscopy-negative reflux disease. <i>Current Gastroenterology Reports</i> , 2001, 3, 206-214.	1.1	20
36	Esomeprazole 20mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of "on-demand" therapy for 6 months. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 347-354.	1.9	173
37	Acid suppression in the management of gastro-oesophageal reflux disease-an appraisal of treatment options in primary care. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 765-772.	1.9	29

#	ARTICLE	IF	CITATIONS
38	The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 927-935.	1.9	113
39	Comparable clinical efficacy and tolerability of 20 mg pantoprazole and 20 mg omeprazole in patients with grade I reflux oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2001, 15, 1585-1591.	1.9	29
40	Nonerosive Reflux Disease— Current Concepts and Dilemmas. <i>American Journal of Gastroenterology</i> , 2001, 96, 303-314.	0.2	246
41	Quality of life in patients with endoscopy-negative heartburn: reliability and sensitivity of disease-specific instruments. <i>American Journal of Gastroenterology</i> , 2001, 96, 1998-2004.	0.2	165
42	Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. <i>American Journal of Gastroenterology</i> , 2001, 96, 27-34.	0.2	148
43	Endoscopic Classification of Gastro-esophageal Reflux Disease. , 2001, , 121-135.		0
44	The Natural History of Gastro-Esophageal Reflux Disease. , 2001, , 71-80.		0
45	Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial. <i>American Journal of Gastroenterology</i> , 2002, 97, 1332-1339.	0.2	143
46	The impact of upper GI endoscopy referral volume on the diagnosis of gastroesophageal reflux disease and its complications: a 1-year cross-sectional study in a referral area with 260,000 inhabitants. <i>American Journal of Gastroenterology</i> , 2002, 97, 2524-2529.	0.2	51
47	Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. <i>Gut</i> , 2002, 51, 472-474.	6.1	17
48	Management of reflux disease. <i>Gut</i> , 2002, 50, iv67-iv71.	6.1	7
49	Acid suppression in gastro-oesophageal reflux disease: Why? How? How much and when?. <i>Postgraduate Medical Journal</i> , 2002, 78, 465-468.	0.9	8
50	Definitions of reflux disease and its separation from dyspepsia. <i>Gut</i> , 2002, 50, iv17-iv20.	6.1	20
51	Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 857-863.	0.8	113
52	A double-blind, randomized comparison of omeprazole Multiple Unit Pellet System (MUPS) 20 mg, lansoprazole 30 mg and pantoprazole 40 mg in symptomatic reflux oesophagitis followed by 3 months of omeprazole MUPS maintenance treatment: a Dutch multicentre trial. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 649-656.	0.8	28
53	Cost Effectiveness of Esomeprazole Compared with Omeprazole in the Acute Treatment of Patients with Reflux Oesophagitis in the UK. <i>Pharmacoeconomics</i> , 2002, 20, 279-287.	1.7	9
54	Esomeprazole. <i>Drugs</i> , 2002, 62, 1091-1118.	4.9	18
55	Esomeprazole. <i>Drugs</i> , 2002, 62, 1503-1538.	4.9	135

#	ARTICLE	IF	CITATIONS
56	Laparoscopic fundoplication is the treatment of choice for gastro-oesophageal reflux disease. <i>Gut</i> , 2002, 51, 468-471.	6.1	17
57	Effect of Profound Acid Suppression in Functional Dyspepsia: a Double-Blind, Randomized, Placebo-Controlled Trial. <i>Scandinavian Journal of Gastroenterology</i> , 2002, 37, 1395-1402.	0.6	85
58	Cost Effectiveness of Proton Pump Inhibitors in Gastro-Oesophageal Reflux Disease Without Oesophagitis. <i>Pharmacoeconomics</i> , 2002, 20, 267-277.	1.7	42
59	Gastroesophageal reflux disease revisited. <i>Gastroenterology Clinics of North America</i> , 2002, 31, S1-S10.	1.0	23
61	Early Relief of Upper Gastrointestinal Dyspeptic Symptoms: A Survey of Empirical Therapy with Pantoprazole in Canadian Clinical Practice. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2002, 16, 439-450.	1.8	6
62	Functional heartburn. Current Treatment Options in <i>Gastroenterology</i> , 2002, 5, 251-258.	0.3	9
63	Pharmacologic management of gastroesophageal reflux disease. Current Treatment Options in <i>Gastroenterology</i> , 2002, 5, 301-310.	0.3	6
64	Pharmacologic management of gastroesophageal reflux disease. <i>Current Gastroenterology Reports</i> , 2002, 4, 218-224.	1.1	5
65	Austrian experiences of antireflux surgery. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2002, 16, 1350-1353.	1.3	2
66	Cost-Effectiveness and Cost-Utility of Long-Term Management Strategies for Heartburn. <i>Value in Health</i> , 2002, 5, 312-328.	0.1	26
67	Treatment of mild and severe cases of GERD. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 73-78.	1.9	25
68	The clinical and economic impact of competing management strategies for gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 261-273.	1.9	49
69	Systematic review: patient-centred endpoints in economic evaluations of gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 1469-1480.	1.9	14
70	Health-related quality of life and gastrointestinal disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2002, 17, S72-S84.	1.4	65
71	Outcome of Laparoscopic Antireflux Surgery in Patients With Nonerosive Reflux Disease. <i>Journal of Gastrointestinal Surgery</i> , 2002, 6, 730-737.	0.9	21
72	Validation of a new method of measuring esophageal acid exposure: comparison with 24-hour pH monitoring. <i>Digestive Diseases and Sciences</i> , 2003, 48, 16-21.	1.1	6
73	Surgical outcome in gastro-esophageal reflux disease patients with inadequate response to proton pump inhibitors. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2003, 17, 1029-1035.	1.3	40
74	Clinical Outcomes After Laparoscopic Antireflux Surgery in Patients With and Without Preoperative Endoscopic Esophagitis. <i>Journal of Gastrointestinal Surgery</i> , 2003, 7, 44-52.	0.9	37

#	ARTICLE	IF	CITATIONS
75	Short-term treatment of gastroesophageal reflux disease. <i>Journal of General Internal Medicine</i> , 2003, 18, 755-763.	1.3	51
76	New developments in the pathophysiology of gastro-oesophageal reflux disease (GERD): implications for patient management. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 43-51.	1.9	18
77	Management of mild and severe gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 52-56.	1.9	26
78	Esomeprazole 20mg and lansoprazole 15mg in maintaining healed reflux oesophagitis: Metropole study results. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 333-341.	1.9	99
79	Reflux symptoms in general practice: diagnostic evaluation of the Carlsson-Dent gastro-oesophageal reflux disease questionnaire. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 1049-1055.	1.9	35
80	Once-daily pantoprazole 40mg and esomeprazole 40mg have equivalent overall efficacy in relieving GERD-related symptoms. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 587-594.	1.9	58
81	Direct comparative trials of the efficacy of proton pump inhibitors in the management of gastro-oesophageal reflux disease and peptic ulcer disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 559-568.	1.9	71
82	The basis for the decreased response to proton pump inhibitors in gastro-oesophageal reflux disease patients without erosive oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 18, 891-905.	1.9	24
83	Overview of medical therapy for gastroesophageal disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2003, 13, 57-68.	0.6	5
84	Unsolved problems in the management of patients with gastro-oesophageal reflux disease. <i>Digestive and Liver Disease</i> , 2003, 35, 843-848.	0.4	21
85	Epidemiology and Pathophysiology of Symptomatic Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, S2-S7.	0.2	119
86	Diagnosis of Symptomatic Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, S15-S23.	0.2	59
87	Factors That Influence Therapeutic Outcomes in Symptomatic Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, S24-S30.	0.2	32
88	Goals of Therapy and Guidelines for Treatment Success in Symptomatic Gastroesophageal Reflux Disease Patients. <i>American Journal of Gastroenterology</i> , 2003, 98, S31-S39.	0.2	69
89	Rabeprazole-Based Therapy in The Management of Symptomatic Gastroesophageal Reflux Disease. <i>American Journal of Gastroenterology</i> , 2003, 98, S49-S55.	0.2	12
90	Improving Health-Related Quality of Life in Gastro-Oesophageal Reflux Disease. <i>Drugs</i> , 2003, 63, 2307-2316.	4.9	11
91	Efficacy of laparoscopic antireflux surgery in patients with Barrett's esophagus. <i>American Journal of Surgery</i> , 2003, 186, 652-659.	0.9	42
92	Medical management of patients with esophageal or supraesophageal gastroesophageal reflux disease. <i>American Journal of Medicine</i> , 2003, 115, 179-187.	0.6	15

#	ARTICLE	IF	CITATIONS
93	The Impact of Treatment for Gastro-Oesophageal Reflux Disease on Health-Related Quality of Life. <i>Pharmacoeconomics</i> , 2003, 21, 769-790.	1.7	44
94	Gastroesophageal Reflux Disease. <i>Gastroenterology Nursing</i> , 2003, 26, 195-200.	0.2	7
95	Pantoprazole Rapidly Improves Health-Related Quality of Life in Patients With Heartburn. <i>Journal of Clinical Gastroenterology</i> , 2003, 37, 132-138.	1.1	23
96	Evidence-based assessment of the efficacy of esomeprazole for the healing of erosive esophagitis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2004, 4, 371-382.	0.7	1
97	Review of rabeprazole in the treatment of gastro-oesophageal reflux disease. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 137-149.	0.9	9
98	Assessment of reflux symptom severity: methodological options and their attributes. <i>Gut</i> , 2004, 53, iv28-iv34.	6.1	26
99	Treatment of Gastroesophageal Reflux Disease in Adults: An Individualized Approach. <i>Digestive Diseases</i> , 2004, 22, 148-160.	0.8	15
100	Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs. <i>Gut</i> , 2004, 53, iv1-iv24.	6.1	100
101	Complete Elimination of Reflux Symptoms Does not Guarantee Normalization of Intraesophageal and Intragastric pH in Patients with Gastroesophageal Reflux Disease (GERD). <i>American Journal of Gastroenterology</i> , 2004, 99, 991-996.	0.2	88
102	Gastroesophageal Reflux Disease: A Typical Spectrum Disease (A New Conceptual Framework is Not) <i>Tj ETQq1 1 0.784314 rgBT /Over</i>	0.2	76
103	Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. <i>Ecological Management and Restoration</i> , 2004, 17, 274-278.	0.2	61
104	Definition and diagnosis of gastroesophageal reflux disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S26-S32.	1.4	12
105	Non-pharmacologic treatment strategies in gastroesophageal reflux disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2004, 19, S44-S48.	1.4	4
106	Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 112-117.	1.9	79
107	The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 413-421.	1.9	87
108	Review article: trials on reflux disease - the role of acid secretion and inhibition. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 2-8.	1.9	6
109	Review article: gastro-oesophageal reflux disease - how wide is its span?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 27-37.	1.9	11
110	Review article: gastric pH - the most relevant predictor of benefit in reflux disease?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 19-26.	1.9	55

#	ARTICLE	IF	CITATIONS
111	Review article: gastro-oesophageal reflux disease as a functional gastrointestinal disorder. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 50-55.	1.9	12
112	Approaches to endoscopic-negative reflux disease: part of the GERD spectrum or a unique acid-related disorder?. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 19, 28-34.	1.9	85
113	Evaluation of treatment for gastro-oesophageal reflux disease with a proton pump inhibitor, and relationship between gastro-oesophageal reflux disease and <i>Helicobacter pylori</i> infection in Japan. <i>Alimentary Pharmacology and Therapeutics</i> , 2004, 20, 102-106.	1.9	6
114	On-Demand Therapy with Rabeprazole in Nonerosive and Erosive Gastroesophageal Reflux Disease in Clinical Practice: Effectiveness, Health-Related Quality of Life, and Patient Satisfaction. <i>Digestive Diseases and Sciences</i> , 2004, 49, 931-936.	1.1	37
115	Heartburn in primary care: problems below the surface. <i>Journal of Gastroenterology</i> , 2004, 39, 1027-1034.	2.3	8
117	Endoscopy-negative reflux disease: Concepts and clinical practice. <i>The American Journal of Medicine: Supplement</i> , 2004, 117, 36-43.	1.7	16
118	Are there unmet needs in acid suppression?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2004, 18, 67-72.	1.0	18
119	Risk Factors for Erosive Esophagitis: A Multivariate Analysis Based on the ProGERD Study Initiative. <i>American Journal of Gastroenterology</i> , 2004, 99, 1652-1656.	0.2	182
120	Health State Utilities in Gastroesophageal Reflux Disease Patients with Heartburn: A Study in Germany and Sweden. <i>Medical Decision Making</i> , 2004, 24, 40-52.	1.2	20
121	Natural history of gastro-oesophageal reflux disease without oesophagitis (NERD) – a reappraisal 10 years on. <i>Digestive and Liver Disease</i> , 2004, 36, 111-115.	0.4	73
122	Combined multichannel intraluminal impedance and pH-metry: a novel technique to improve detection of gastro-oesophageal reflux. <i>Digestive and Liver Disease</i> , 2004, 36, 565-569.	0.4	75
123	The Yield of Upper Gastrointestinal Endoscopy in Patients with Suspected Reflux-Related Chronic Ear, Nose, and Throat Symptoms. <i>American Journal of Gastroenterology</i> , 2004, 99, 1419-1426.	0.2	79
124	The Role of Proton Pump Inhibitors in Gastro-oesophageal Reflux Disease. <i>Drugs</i> , 2004, 64, 277-295.	4.9	51
125	Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. , 2004, , CD003245.		74
126	Risk factors of gastroesophageal reflux disease: methodology and first epidemiological results of the ProGERD study. <i>Journal of Clinical Epidemiology</i> , 2004, 57, 580-589.	2.4	149
127	Medical and surgical management of gastroesophageal reflux disease. <i>Clinics in Family Practice</i> , 2004, 6, 547-568.	0.3	4
128	Efficacy of Esomeprazole in Patients With Acid-Peptic Disorders. <i>Gastroenterology Nursing</i> , 2004, 27, 44-49.	0.2	7
129	Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2004, 38, 390-402.	1.1	28

#	ARTICLE	IF	CITATIONS
130	Short-Term Treatment with Proton-Pump Inhibitors as a Test for Gastroesophageal Reflux Disease. <i>Annals of Internal Medicine</i> , 2004, 140, 518.	2.0	304
131	Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. , 2004, , CD002095.		46
132	A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6 months in the management of patients with symptoms of gastroesophageal reflux disease. <i>International Journal of Clinical Practice</i> , 2005, 59, 665-671.	0.8	19
133	Long-term management of patients with symptoms of gastro-oesophageal reflux disease - a Norwegian randomised prospective study comparing the effects of esomeprazole and ranitidine treatment strategies on health-related quality of life in a general practit. <i>International Journal of Clinical Practice</i> , 2005, 60, 15-22.	0.8	27
134	Endoscopy-negative reflux disease: part of the spectrum of non-steroidal anti-inflammatory drug or a separate disorder? Implications for treatment. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 9-10.	1.9	3
135	Heartburn-dominant, uninvestigated dyspepsia: a comparison of 'PPI-start' and 'H2-RA-start' management strategies in primary care - the CADET-HR Study. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1189-1202.	1.9	53
136	Famotidine vs. omeprazole: a prospective randomized multicentre trial to determine efficacy in non-erosive gastro-oesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 10-18.	1.9	35
137	Systematic review: the efficacy of intermittent and on-demand therapy with histamine H2-receptor antagonists or proton pump inhibitors for gastro-oesophageal reflux disease patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 21, 1299-1312.	1.9	49
138	Systematic review: proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next?. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 79-94.	1.9	341
139	Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 635-643.	1.9	11
140	Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. <i>Alimentary Pharmacology and Therapeutics</i> , 2005, 22, 10-19.	1.9	46
141	A poor response to proton pump inhibition is not a contraindication for laparoscopic antireflux surgery for gastro esophageal reflux disease. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2005, 19, 1272-1277.	1.3	26
142	Characteristics of symptomatic GERD in Japanese patients based on 24-h pH monitoring. <i>Journal of Gastroenterology</i> , 2005, 40, 791-795.	2.3	4
143	The Value of Ambulatory 24 hr Esophageal pH Monitoring in Clinical Practice in Patients Who Were Referred with Persistent Gastroesophageal Reflux Disease (GERD)-Related Symptoms While on Standard Dose Anti-Reflux Medications. <i>Digestive Diseases and Sciences</i> , 2005, 50, 1909-1915.	1.1	39
144	Efficacy of Rabeprazole in the Treatment of Symptomatic Gastroesophageal Reflux Disease. <i>Digestive Diseases and Sciences</i> , 2005, 50, 2009-2018.	1.1	45
145	Canadian Consensus Conference on the Management of Gastroesophageal Reflux Disease in Adults â€” Update 2004. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 15-35.	1.8	204
146	Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2005, 19, 285-303.	1.8	70
147	Prevalence of heartburn and gastroesophageal reflux disease in the urban Brazilian population. <i>Arquivos De Gastroenterologia</i> , 2005, 42, 122-127.	0.3	84

#	ARTICLE	IF	CITATIONS
148	Treatment of uncomplicated reflux disease. World Journal of Gastroenterology, 2005, 11, 4291.	1.4	60
149	Head-to-head comparison of H ₂ -receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis. World Journal of Gastroenterology, 2005, 11, 4067.	1.4	63
150	Rabeprazolevsesomeprazole in non-erosive gastro-esophageal reflux disease: A randomized, double-blind study in urban Asia. World Journal of Gastroenterology, 2005, 11, 3091.	1.4	46
151	Managing Gastroesophageal Reflux Disease in Primary Care: The Patient Perspective. Journal of the American Board of Family Medicine, 2005, 18, 393-400.	0.8	59
154	Differences in Clinical Characteristics between Patients with Endoscopy-Negative Reflux Disease and Erosive Esophagitis in Japan. American Journal of Gastroenterology, 2005, 100, 754-758.	0.2	88
155	Early Heartburn Relief With Proton Pump Inhibitors: A Systematic Review and Meta-analysis of Clinical Trials. Clinical Gastroenterology and Hepatology, 2005, 3, 553-563.	2.4	39
156	Association Between Dinner-to-Bed Time and Gastro-Esophageal Reflux Disease. American Journal of Gastroenterology, 2005, 100, 2633-2636.	0.2	95
157	Gastroesophageal reflux. European Journal of Internal Medicine, 2005, 16, 391-401.	1.0	4
158	Acid normalization and improved esophageal motility after Nissen fundoplication: equivalent outcomes in patients with normal and ineffective esophageal motility. American Journal of Surgery, 2005, 190, 445-450.	0.9	34
159	Pilot Study of On-Demand Therapy with Pantoprazole 20mg for Long-Term Treatment in Patients with Mild Gastro-Oesophageal Reflux Disease. Clinical Drug Investigation, 2005, 25, 633-642.	1.1	3
160	Routine management of gastro-oesophageal reflux disease by gastroenterologists in France: A prospective observational study. Digestive and Liver Disease, 2005, 37, 566-570.	0.4	8
161	Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: Still an unexplored triangle. Digestive and Liver Disease, 2005, 37, 468-474.	0.4	10
162	Impact of referral for gastro-oesophageal reflux disease on the workload of an academic Gastroenterology Unit. Digestive and Liver Disease, 2005, 37, 735-740.	0.4	9
163	Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. Digestive and Liver Disease, 2005, 37, 741-750.	0.4	27
164	Diagnostic Value of Potent Acid Inhibition in Gastro-Oesophageal Reflux Disease. Drugs, 2005, 65, 35-42.	4.9	3
165	Valutazione economica della terapia di mantenimento al bisogno con esomeprazolo nella malattia da reflusso gastroesofageo. Pharmacoeconomics Italian Research Articles, 2005, 7, 67-80.	0.2	2
166	Short-term treatment with proton pump inhibitors, H ₂ -receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. , 2006, , CD002095.		58
167	Gastroesophageal Reflux Symptoms and Well-Being in a Random Sample of the General Population of a Swedish Community. American Journal of Gastroenterology, 2006, 101, 18-28.	0.2	120

#	ARTICLE	IF	CITATIONS
168	Maintenance of Healed Erosive Esophagitis: A Randomized Six-Month Comparison of Esomeprazole Twenty Milligrams With Lansoprazole Fifteen Milligrams. <i>Clinical Gastroenterology and Hepatology</i> , 2006, 4, 852-859.	2.4	46
169	An update on the available treatments for non-erosive reflux disease. <i>Expert Opinion on Pharmacotherapy</i> , 2006, 7, 47-56.	0.9	11
170	Psychological factors as a predictor of treatment response in patients with heartburn: A pooled analysis of clinical trials. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 288-293.	0.6	31
171	Manejo cl�nico de la enfermedad por reflujo gastroesof�gico. <i>FMC Formacion Medica Continuada En Atencion Primaria</i> , 2006, 13, 217-229.	0.0	0
172	An evidence-based, Latin-American consensus on gastro-oesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2006, 18, 349-368.	0.8	6
173	Advantages and disadvantages of lumping together gastroesophageal reflux disease and dyspepsia. <i>Current Opinion in Gastroenterology</i> , 2006, 22, 412-416.	1.0	0
174	Increased Esophageal Sensitivity to Acid and Saline in Patients With Nonerosive Gastro-esophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2006, 40, 891-895.	1.1	59
175	"On-demand" therapy for gastroesophageal reflux disease: Are current proton pump inhibitors good candidates?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, S115-S118.	1.4	1
176	Proton-pump inhibitor failure/resistance: Proposed mechanisms and therapeutic algorithm. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, S119-S124.	1.4	4
177	Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 23, 33-39.	1.9	19
178	Antireflux surgery for non-erosive and erosive reflux disease in community practice. <i>Alimentary Pharmacology and Therapeutics</i> , 2006, 24, 621-632.	1.9	24
179	Therapeutic Effects of Laparoscopic Fundoplication for Nonerosive Gastroesophageal Reflux Disease. <i>Surgery Today</i> , 2006, 36, 954-960.	0.7	11
180	The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. <i>Journal of Gastroenterology</i> , 2006, 41, 554-561.	2.3	15
181	Outcome research in gastroenterology: the case of gastroesophageal reflux disease (GERD). <i>Drug Development Research</i> , 2006, 67, 251-259.	1.4	1
182	Dilated Intercellular Spaces. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2006, 42, 510-515.	0.9	70
184	Refractory Heartburn to Proton Pump Inhibitors: Epidemiology, Etiology and Management. <i>Digestion</i> , 2006, 73, 218-227.	1.2	21
185	Potential Options to Optimize Therapy of Gastroesophageal Reflux Disease with Proton Pump Inhibitors. <i>Digestion</i> , 2007, 76, 171-178.	1.2	2
186	Empirical Therapy for Symptomatic Gastroesophageal Reflux Disease in Primary Care: Determinants of Efficacy. <i>Digestion</i> , 2007, 76, 207-214.	1.2	5

#	ARTICLE	IF	CITATIONS
187	Sleep Dysfunction in Patients With GERD: Erosive Versus Nonerosive Reflux Disease. <i>American Journal of the Medical Sciences</i> , 2007, 334, 168-170.	0.4	32
188	Global Clinical Symptom Spectrum in Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, S168-S174.	1.1	2
189	Erosive Esophagitis and Nonerosive Reflux Disease (NERD). <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 131-137.	1.1	234
190	Psychological Factors, Quality of Life, and Gastrointestinal Symptoms in Patients with Erosive and Non-Erosive Reflux Disorder. <i>International Journal of Psychiatry in Medicine</i> , 2007, 37, 139-150.	0.8	20
191	Distinct Clinical Characteristics Between Patients With Nonerosive Reflux Disease and Those With Reflux Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2007, 5, 690-695.	2.4	97
192	Proton-Pump Inhibitor Therapy in Patients with Gastro-Oesophageal Reflux Disease. <i>Drugs</i> , 2007, 67, 1521-1530.	4.9	82
193	Pantoprazole On-Demand Effectively Treats Symptoms in Patients with Gastro-Oesophageal Reflux Disease. <i>Clinical Drug Investigation</i> , 2007, 27, 287-296.	1.1	8
194	The lessons learned from randomized clinical trials of GERD. <i>Digestive and Liver Disease</i> , 2007, 39, 993-1000.	0.4	2
195	Prospective Acid Reflux Study of Iran (PARSI): Methodology and study design. <i>BMC Gastroenterology</i> , 2007, 7, 42.	0.8	13
196	Defective triggering of secondary peristalsis in patients with non-erosive reflux disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 2208-2211.	1.4	39
197	Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2007, 22, 1286-1292.	1.4	17
198	Perceptions and practices on the management of gastroesophageal reflux disease: results of a national survey comparing primary care physicians and gastroenterologists. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 25, 823-833.	1.9	19
199	The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 173-185.	1.9	155
200	Acid-related oesophageal sensitivity, not dysmotility, differentiates subgroups of patients with non-erosive reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 396-403.	1.9	46
201	Management of gastro-esophageal reflux disease in primary care. Results from an observational study of 2 474 patients. <i>Gastroenterologie Clinique Et Biologique</i> , 2007, 31, 72-77.	0.9	12
202	Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions—a debate: Con. <i>Current GERD Reports</i> , 2007, 1, 267-272.	0.1	1
204	Validity of endoscopic classification of nonerosive reflux disease. <i>Journal of Gastroenterology</i> , 2007, 42, 444-449.	2.3	49
205	Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions—a debate: Con. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 305-311.	0.3	8

#	ARTICLE	IF	CITATIONS
206	A Glass of Water Immediately Increases Gastric pH in Healthy Subjects. <i>Digestive Diseases and Sciences</i> , 2008, 53, 3128-3132.	1.1	18
208	Gastro-esophageal reflux disease: the recent trend in Japan. <i>Clinical Journal of Gastroenterology</i> , 2008, 1, 133-138.	0.4	16
209	Efficacy and safety of omeprazole in Japanese patients with nonerosive reflux disease. <i>Journal of Gastroenterology</i> , 2008, 43, 670-678.	2.3	34
210	The influence of comorbid IBS and psychological distress on outcomes and quality of life following PPI therapy in patients with gastroesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 27, 473-482.	1.9	91
211	Gastro-Oesophageal Reflux Disease in Asia. <i>Drugs</i> , 2008, 68, 399-406.	4.9	15
214	A Randomized, Comparative Trial of a Potassium-Competitive Acid Blocker (AZD0865) and Esomeprazole for the Treatment of Patients With Nonerosive Reflux Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 20-26.	0.2	92
215	Multivariate analysis of the association of acid and duodeno-gastro-oesophageal reflux exposure with the presence of oesophagitis, the severity of oesophagitis and Barrett's oesophagus. <i>Gut</i> , 2008, 57, 1056-1064.	6.1	63
217	Esophageal Dilated Intercellular Spaces (DIS) and Nonerosive Reflux Disease. <i>American Journal of Gastroenterology</i> , 2008, 103, 1021-1028.	0.2	141
218	Outcomes of different treatment approaches for gastro-oesophageal reflux disease. , 2008, , 17-27.		0
219	How Relevant Is Symptom Evaluation in NERD?. <i>Digestion</i> , 2008, 78, 11-16.	1.2	0
220	Precise Role of Acid in Non-Erosive Reflux Disease. <i>Digestion</i> , 2008, 78, 31-41.	1.2	18
221	Visceral hypersensitivity in non-erosive reflux disease. <i>Gut</i> , 2008, 57, 674-683.	6.1	163
222	Gastroesophageal Reflux Disease. <i>Annals of Internal Medicine</i> , 2008, 149, ITC2-1.	2.0	6
223	Symptom Evaluation in Gastroesophageal Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 558-563.	1.1	10
224	Objective Measurement of Work Absence and On-The-Job Productivity: A Case-Control Study of US Employees With and Without Gastroesophageal Reflux Disease. <i>Journal of Occupational and Environmental Medicine</i> , 2008, 50, 25-31.	0.9	28
225	The nonerosive reflux disease???gastroesophageal reflux disease controversy. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 509-515.	1.0	20
226	Effect of Proton-Pump Inhibitor Treatment on Symptoms and Quality of Life in GERD Patients Depends on the Symptom-reflux Association. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 441-447.	1.1	37
227	Dilated intercellular spaces in gastroesophageal reflux disease patients and the changes of intercellular spaces after omeprazole treatment. <i>Chinese Medical Journal</i> , 2008, 121, 1297-1301.	0.9	23

#	ARTICLE	IF	CITATIONS
228	Impact of PPIs on patient focused symptomatology in GERD. Therapeutics and Clinical Risk Management, 2008, Volume 4, 1185-1200.	0.9	4
229	Proton Pump Inhibitor Failure—What Are the Therapeutic Options?. American Journal of Gastroenterology, 2009, 104, S33-S38.	0.2	1
230	Proton Pump Inhibitor Failure—What Are the Therapeutic Options?. American Journal of Gastroenterology, 2009, 104, S33-S38.	0.2	84
231	Two-year results of a feasibility study on antireflux transoral incisionless fundoplication using EsophyX. Surgical Endoscopy and Other Interventional Techniques, 2009, 23, 957-964.	1.3	98
232	The Effect of Gastroesophageal Flap Valve Appearance on the Management of Patients with Symptoms of Gastroesophageal Reflux Disease. Digestive Diseases and Sciences, 2009, 54, 328-332.	1.1	9
233	Hiatal Hernia, Lower Esophageal Sphincter Incompetence, and Effectiveness of Nissen Fundoplication in the Spectrum of Gastroesophageal Reflux Disease. Journal of Gastrointestinal Surgery, 2009, 13, 602-610.	0.9	127
234	Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation—results from two randomized controlled studies. Alimentary Pharmacology and Therapeutics, 2009, 29, 731-741.	1.9	110
235	Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis. Alimentary Pharmacology and Therapeutics, 2009, 29, 742-754.	1.9	65
236	Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy. Alimentary Pharmacology and Therapeutics, 2009, 29, 928-937.	1.9	106
237	Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease. Alimentary Pharmacology and Therapeutics, 2009, 29, 1261-1272.	1.9	82
238	Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease. Alimentary Pharmacology and Therapeutics, 2009, 30, 154-164.	1.9	55
239	Clinical trial: efficacy and safety of dexlansoprazole MR 60 and 90-mg in healed erosive oesophagitis—maintenance of healing and symptom relief. Alimentary Pharmacology and Therapeutics, 2009, 30, 895-907.	1.9	39
240	Endoscopy of the esophagus in gastroesophageal reflux disease: are we losing sight of symptoms? Another perspective. Ecological Management and Restoration, 2009, 22, 461-466.	0.2	8
241	Chiropractic manual intervention in chronic adult dyspepsia: A pilot study. Clinical Chiropractic, 2009, 12, 28-34.	0.1	4
242	Dexlansoprazole MR. Expert Opinion on Pharmacotherapy, 2009, 10, 2329-2336.	0.9	17
243	Functional Heartburn: What It Is and How to Treat It. Gastrointestinal Endoscopy Clinics of North America, 2009, 19, 23-33.	0.6	20
244	Management of heartburn not responding to proton pump inhibitors. Gut, 2009, 58, 295-309.	6.1	267
245	Predictors of heartburn resolution and erosive esophagitis in patients with GERD. Current Medical Research and Opinion, 2009, 25, 2091-2102.	0.9	9

#	ARTICLE	IF	CITATIONS
246	Proton pump inhibitors in GORDAn overview of their pharmacology, efficacy and safety. <i>Pharmacological Research</i> , 2009, 59, 135-153.	3.1	156
247	Comparison of Reflux Frequency During Prolonged Multichannel Intraluminal Impedance and pH Monitoring On and Off Acid Suppression Therapy. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 816-820.	1.1	47
248	Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease. <i>The Cochrane Library</i> , 2010, , CD003245.	1.5	49
249	Gastro-oesophageal reflux disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 757-758.	1.0	2
250	Gastroesophageal reflux disease. <i>Journal of Gastroenterology</i> , 2010, 45, 808-815.	2.3	18
251	Long-term outcome of Nissen fundoplication in non-erosive and erosive gastro-oesophageal reflux disease. <i>British Journal of Surgery</i> , 2010, 97, 845-852.	0.1	57
252	A pragmatic symptom-based approach. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 765-773.	1.0	2
253	Mosapride as an adjunct to lansoprazole for symptom relief of reflux oesophagitis. <i>British Journal of Clinical Pharmacology</i> , 2010, 70, 171-179.	1.1	27
254	Clinical trial: maintenance intermittent therapy with rabeprazole 20â€ƒmg in patients with symptomatic gastroâ€œoesophageal reflux disease â€œ a doubleâ€œblind, placeboâ€œcontrolled, randomized study. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 31, 950-960.	1.9	10
255	Metaâ€œanalysis: the effects of placebo treatment on gastroâ€œoesophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 29-42.	1.9	52
256	The impact of preâ€œendoscopy proton pump inhibitor use on the classification of nonâ€œerosive reflux disease and erosive oesophagitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2010, 32, 1266-1274.	1.9	21
257	Serum lipid levels are positively associated with nonâ€œerosive reflux disease, but not with functional heartburn. <i>Neurogastroenterology and Motility</i> , 2010, 22, 965.	1.6	10
258	Reversal of the tolerance phenomenon by the intermittent administration of a histamine H2â€œreceptor antagonist. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2010, 25, 1493-1497.	1.4	3
260	The Role of Weakly Acidic Reflux in Proton Pump Inhibitor Failure, Has Dust Settled?. <i>Journal of Neurogastroenterology and Motility</i> , 2010, 16, 258-264.	0.8	38
261	Differences in Clinical Characteristics between Patients with Non-Erosive Reflux Disease and Erosive Esophagitis in Korea. <i>Journal of Korean Medical Science</i> , 2010, 25, 1318.	1.1	19
262	Nonerosive Reflux Disease (NERD) - An Update. <i>Journal of Neurogastroenterology and Motility</i> , 2010, 16, 8-21.	0.8	113
263	Are functional heartburn and functional dyspepsia one disorder?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2010, 7, 71-72.	8.2	12
264	Upper GI tract findings in patients with heartburn in whom proton pump inhibitor treatment failed versus those not receiving antireflux treatment. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 28-34.	0.5	124

#	ARTICLE	IF	CITATIONS
265	Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. , 2010, , CD002095.		48
266	Insights Into Gastroesophageal Reflux Diseaseâ€“Associated Dyspeptic Symptoms. Clinical Gastroenterology and Hepatology, 2011, 9, 824-833.	2.4	73
267	Overweight is a risk factor for both erosive and non-erosive reflux disease. Digestive and Liver Disease, 2011, 43, 940-945.	0.4	52
268	Burden of Gastro-Oesophageal Reflux Disease in Patients with Persistent and Intense Symptoms Despite Proton Pump Inhibitor Therapy. Clinical Drug Investigation, 2011, 31, 703-715.	1.1	43
269	Endoscopic grading of gastroesophageal flap valve helps predict proton pump inhibitor response in patients with gastroesophageal reflux disease. Scandinavian Journal of Gastroenterology, 2011, 46, 789-796.	0.6	23
271	Silent gastroesophageal disease: Clinical implications of an unknown disease. Journal of Gastroenterology and Hepatology (Australia), 2011, 26, 941-942.	1.4	3
272	Non-Erosive Reflux Disease (NERD), Symptomatic and Asymptomatic Erosive Reflux Disease (ERD): From Hypersensitive to Hyposensitive Esophagus. Digestive Diseases and Sciences, 2011, 56, 90-96.	1.1	22
273	Clinical and pH-metric outcomes of transoral esophagogastric fundoplication for the treatment of gastroesophageal reflux disease. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 1975-1984.	1.3	64
274	Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trial. Journal of Gastroenterology, 2011, 46, 906-912.	2.3	12
275	Nonerosive reflux disease as a presentation of gastro-oesophageal reflux disease. South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care, 2011, 53, 326-331.	0.2	0
276	Response to Air Insufflation in Patients with Non-Erosive Gastro-Oesophageal Reflux Disease (NERD). Journal of International Medical Research, 2011, 39, 215-221.	0.4	0
277	Trypsin impaired epithelial barrier function and induced IL-8 secretion through basolateral PAR-2: a lesson from a stratified squamous epithelial model. American Journal of Physiology - Renal Physiology, 2012, 303, G1105-G1112.	1.6	26
279	A randomized open-label trial of on-demand rabeprazole<i>vs</i>ranitidine for patients with non-erosive reflux disease. World Journal of Gastroenterology, 2012, 18, 2390.	1.4	8
280	The herbal medicine rikkunshito exhibits strong and differential adsorption properties for bile salts. Experimental and Therapeutic Medicine, 2012, 3, 645-649.	0.8	16
282	Non-alcoholic fatty liver disease is associated with high prevalence of gastro-oesophageal reflux symptoms. Digestive and Liver Disease, 2012, 44, 1032-1036.	0.4	16
283	Endoscopic management of gastroesophageal reflux disease: A review. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, S74-S79.	0.4	6
284	Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut, 2012, 61, 1340-1354.	6.1	285
285	Nonerosive gastroesophageal reflux disease and mild degree of esophagitis: Comparison of symptoms endoscopic, manometric and pH-metric patterns. World Journal of Surgical Oncology, 2012, 10, 84.	0.8	8

#	ARTICLE	IF	CITATIONS
286	Transoral incisionless fundoplication for treatment of gastroesophageal reflux disease in clinical practice. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 3307-3315.	1.3	49
287	Use of acid suppressive therapy more than 10 years after the endoscopic diagnosis of reflux esophagitis with specific emphasis to trademark and generic proton pump inhibitors. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 368-371.	1.4	1
288	PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysis. <i>Neurogastroenterology and Motility</i> , 2012, 24, 747.	1.6	119
289	Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. <i>The Cochrane Library</i> , 2013, , CD002095.	1.5	214
290	Lifestyle factors associated with gastroesophageal reflux disease in the Japanese population. <i>Journal of Gastroenterology</i> , 2013, 48, 340-349.	2.3	55
291	Patterns of proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. <i>Scandinavian Journal of Gastroenterology</i> , 2013, 48, 1010-1017.	0.6	5
292	Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy. <i>Ecological Management and Restoration</i> , 2013, 26, 443-450.	0.2	38
293	NERD: an umbrella term including heterogeneous subpopulations. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 371-380.	8.2	184
294	Diagnosis and Management of Gastroesophageal Reflux Disease. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-2.	0.7	3
295	Gastro-oesophageal reflux. Part 2: medical treatment. <i>British Journal of Nursing</i> , 2013, 22, 277-284.	0.3	2
296	Symptom-histopathology relation in upper GI endoscopy. <i>Turkish Journal of Surgery</i> , 2013, 29, 115-118.	1.0	1
297	Current Advances in the Diagnosis and Treatment of Nonerosive Reflux Disease. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-8.	0.7	25
298	The Frequencies of Gastroesophageal and Extragastroesophageal Symptoms in Patients with Mild Erosive Esophagitis, Severe Erosive Esophagitis, and Barrett's Esophagus in Taiwan. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-6.	0.7	9
299	Treatment of GORD: Three decades of progress and disappointments. <i>United European Gastroenterology Journal</i> , 2013, 1, 140-150.	1.6	11
300	Sleep Disturbances and Refractory Gastroesophageal Reflux Disease Symptoms in Patients Receiving Once-Daily Proton Pump Inhibitors and Efficacy of Twice-Daily Rabeprazole Treatment. <i>Digestion</i> , 2013, 88, 145-152.	1.2	13
301	Current Pharmacological Management of Gastroesophageal Reflux Disease. <i>Gastroenterology Research and Practice</i> , 2013, 2013, 1-12.	0.7	27
302	Acid Sensitization of Esophageal Mucosal Afferents. <i>Clinical Journal of Pain</i> , 2013, 29, 70-77.	0.8	13
303	Determinants of symptoms in gastroesophageal reflux disease. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 764-771.	0.8	28

#	ARTICLE	IF	CITATIONS
304	Association of Sleep Dysfunction and Emotional Status With Gastroesophageal Reflux Disease in Korea. <i>Journal of Neurogastroenterology and Motility</i> , 2013, 19, 344-354.	0.8	51
305	Outcomes in patients with nonerosive reflux disease treated with a proton pump inhibitor and alginate acid & plusmn; glycyrrhetic acid and anthocyanosides. <i>Clinical and Experimental Gastroenterology</i> , 2013, 6, 27.	1.0	4
306	Comparison of Gastroesophageal Reflux Disease Symptoms and Proton Pump Inhibitor Response Using Gastroesophageal Reflux Disease Impact Scale Questionnaire. <i>Journal of Neurogastroenterology and Motility</i> , 2013, 19, 61-69.	0.8	17
307	Effects of the New Prokinetic Agent DA-9701 Formulated With Corydalis Tuber and Pharbitis Seed in Patients With Minimal Change Esophagitis: A Bicenter, Randomized, Double Blind, Placebo-controlled Study. <i>Journal of Neurogastroenterology and Motility</i> , 2014, 20, 338-346.	0.8	12
309	Comparing omeprazole with fluoxetine for treatment of patients with heartburn and normal endoscopy who failed once daily proton pump inhibitors: Double-blind placebo-controlled trial. <i>Neurogastroenterology and Motility</i> , 2014, 26, 670-678.	1.6	59
310	Sensiprobe—a miniature thermal device incorporating Peltier technology as a diagnostic tool for studying human oesophageal sensitivity. <i>Physiological Measurement</i> , 2014, 35, 1265-1277.	1.2	3
311	Esophageal Mucosal Integrity in Nonerosive Reflux Disease. <i>Journal of Clinical Gastroenterology</i> , 2014, 48, 6-12.	1.1	37
312	Mechanisms of Acid Reflux and How Refluxed Acid Extends Proximally in Patients with Non-Erosive Reflux Disease. <i>Digestion</i> , 2014, 90, 108-115.	1.2	8
313	Outcome of Laparoscopic Nissen Fundoplication for Gastroesophageal Reflux Disease in Non-responders to Proton Pump Inhibitors. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 1557-1562.	0.9	31
314	Recurrence of gastroesophageal reflux disease correlated with a short dinner-to-bedtime interval. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2014, 29, 730-735.	1.4	21
316	Patients with refractory reflux symptoms: What do they have and how should they be managed?. <i>Neurogastroenterology and Motility</i> , 2015, 27, 1195-1201.	1.6	46
317	A Novel Sleep Positioning Device Reduces Gastroesophageal Reflux. <i>Journal of Clinical Gastroenterology</i> , 2015, 49, 655-659.	1.1	38
318	Unmet Needs in the Treatment of Gastroesophageal Reflux Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2015, 21, 309-319.	0.8	44
319	Characteristics of Esophageal Motility in Chinese GERD Patients. <i>Journal of Biology and Life Science</i> , 2015, 7, 33.	0.2	0
320	Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritis. <i>World Journal of Gastroenterology</i> , 2015, 21, 6965-6973.	1.4	4
321	Eight Weeks of Esomeprazole Therapy Reduces Symptom Relapse, Compared With 4 Weeks, in Patients With Los Angeles Grade A or B Erosive Esophagitis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 859-866.e1.	2.4	23
322	Risk factors of incomplete response to proton pump inhibitor therapy in patients with mild erosive esophagitis. <i>Advances in Digestive Medicine</i> , 2015, 2, 18-24.	0.1	1
323	Efficacy of laparoscopic Toupet fundoplication for non-erosive reflux disease assessed by combined multichannel intraluminal impedance-pH monitoring. <i>Esophagus</i> , 2015, 12, 219-224.	1.0	0

#	ARTICLE	IF	CITATIONS
324	Management of reflux esophagitis: does the choice of proton pump inhibitor matter?. International Journal of Clinical Practice, 2015, 69, 796-801.	0.8	9
325	PPI-Refractory GERD: an Intriguing, Probably Overestimated, Phenomenon. Current Gastroenterology Reports, 2015, 17, 451.	1.1	3
326	Gastrointestinal Surgery. , 2015, , .		1
327	Severe Reflux-Induced Esophagitis. , 2015, , 73-85.		1
328	The Role of the Acid Pocket in Gastroesophageal Reflux Disease. Journal of Clinical Gastroenterology, 2016, 50, 111-119.	1.1	31
329	Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Medicine, 2016, 14, 179.	2.3	300
330	24-hour pH-impedance monitoring on therapy to select patients with refractory reflux symptoms for antireflux surgery. A single center retrospective study. Neurogastroenterology and Motility, 2016, 28, 146-152.	1.6	43
332	Diagnosis and Treatment of Gastroesophageal Reflux Disease. , 2016, , .		1
333	Role of H2RA and Proton Pump Inhibitor Therapy in Treating Reflux Disease. , 2016, , 71-91.		2
334	Deprescribing versus continuation of chronic proton pump inhibitor use in adults. The Cochrane Library, 2017, 2017, CD011969.	1.5	92
335	Comparison of oesophageal function tests between Chinese non-erosive reflux disease and reflux hypersensitivity patients. BMC Gastroenterology, 2017, 17, 67.	0.8	10
336	Role of Immediate Release and Delayed Release Omeprazole in Patients with Gastro Esophageal Reflux Disease. Faridpur Medical College Journal, 2017, 11, 67-73.	0.0	0
337	Medical Therapy of Gastroesophageal Reflux Disease Beyond Proton Pump Inhibitors: Where Are We Heading?. Visceral Medicine, 2018, 34, 110-115.	0.5	1
338	Modern diagnosis of GERD: the Lyon Consensus. Gut, 2018, 67, 1351-1362.	6.1	991
339	Nonerosive Reflux Disease (NERD). , 2018, , 109-134.		0
340	Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Annals of Gastroenterology, 2018, 31, 639-648.	0.4	68
342	Proton pump inhibitors: use and misuse in the clinical setting. Expert Review of Clinical Pharmacology, 2018, 11, 1123-1134.	1.3	112
343	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1074-1081.	1.9	32

#	ARTICLE	IF	CITATIONS
344	Appropriateness in prescribing PPIs: A position paper of the Italian Society of Gastroenterology (SIGE) " Study section "Digestive Diseases in Primary Care" Digestive and Liver Disease, 2018, 50, 894-902.	0.4	30
345	Gastroesophageal reflux symptoms among Italian university students: epidemiology and dietary correlates using automatically recorded transactions. BMC Gastroenterology, 2018, 18, 116.	0.8	24
346	Acid Suppression for Management of Gastroesophageal Reflux Disease: Benefits and Risks. , 2018, , 269-291.		3
347	Alcohol accumulation promotes esophagitis via pyroptosis activation. International Journal of Biological Sciences, 2018, 14, 1245-1255.	2.6	31
348	Laparoscopic Hiatal Hernia Repair Followed by Transoral Incisionless Fundoplication With EsophyX Device (HH + TIF): Efficacy and Safety in Two Community Hospitals. Surgical Innovation, 2019, 26, 675-686.	0.4	43
349	Beneficial effect of probiotics supplements in reflux esophagitis treated with esomeprazole: A randomized controlled trial. World Journal of Gastroenterology, 2019, 25, 2110-2121.	1.4	21
350	CLINICAL AND ENDOSCOPIC EVALUATION IN PATIENTS WITH GASTROESOPHAGEAL SYMPTOMS. Arquivos De Gastroenterologia, 2019, 56, 51-54.	0.3	5
351	Association of serum gastric inhibitory polypeptide and pancreatic polypeptide levels with prolonged esophageal acid exposure time in refractory gastroesophageal reflux disease. Medicine (United States), 2019, 98, e15965.	0.4	3
352	Assessing different diagnostic tests for gastroesophageal reflux disease: a systematic review and network meta-analysis. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481989053.	1.4	21
353	The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease. Current Opinion in Gastroenterology, 2019, 35, 344-355.	1.0	29
354	Pharmacologic treatment of GERD: Where we are now, and where are we going?. Annals of the New York Academy of Sciences, 2020, 1482, 193-212.	1.8	20
355	Gastrointestinal pharmacology: practical tips for the esophagologist. Annals of the New York Academy of Sciences, 2020, 1481, 90-107.	1.8	7
356	Peroral endoscopic myotomy (POEM) for dysphagia and esophageal motor disorder after antireflux fundoplication. Endoscopy, 2020, 52, 583-588.	1.0	5
357	Prevalence and predictors of proton pump inhibitor partial response in gastroesophageal reflux disease in systemic sclerosis: a prospective study. Scientific Reports, 2020, 10, 769.	1.6	14
358	Stretta procedure versus proton pump inhibitors for the treatment of nonerosive reflux disease. Medicine (United States), 2020, 99, e18610.	0.4	15
359	The role of serotonin in the control of esophageal sensitivity assessed by multimodal stimulation in health. Neurogastroenterology and Motility, 2021, 33, e14057.	1.6	5
360	Gastro-oesophageal reflux disease. Nature Reviews Disease Primers, 2021, 7, 55.	18.1	66
361	Gastric peroral endoscopic myotomy (GPOEM) for severe gastroparesis after lung transplantation: A promising minimally invasive option. Clinical Transplantation, 2021, 35, e14434.	0.8	7

#	ARTICLE	IF	CITATIONS
362	Effectiveness and Costs of Omeprazole vs Ranitidine for Treatment of Symptomatic Gastroesophageal Reflux Disease in Primary Care Clinics in West Virginia. <i>Archives of Family Medicine</i> , 2000, 9, 624-630.	1.5	48
364	<i>Clinical Spectrum, Natural History and Epidemiology of GERD.</i> , 2006, , 1-11.		5
365	<i>Gastro-oesophageal reflux disease.</i> , 1999, , 223-235.		1
366	Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease1. <i>American Journal of Gastroenterology</i> , 2001, 96, 2849-2857.	0.2	10
367	Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. <i>American Journal of Gastroenterology</i> , 2001, 96, 2849-57.	0.2	63
368	ESNM/ANMS consensus paper: Diagnosis and management of refractory gastroesophageal reflux disease. <i>Neurogastroenterology and Motility</i> , 2021, 33, e14075.	1.6	68
369	Treatment of gastro-oesophageal reflux disease in adults. <i>BMJ: British Medical Journal</i> , 1999, 318, 59-59.	2.4	2
370	GERD 2003 – A Consensus on the Way Ahead. <i>Digestion</i> , 2003, 67, 111-117.	1.2	41
371	Esophagitis in a High <i>H. pylori</i> Prevalence Area: Severe Disease Is Rare but Concomitant Peptic Ulcer Is Frequent. <i>PLoS ONE</i> , 2011, 6, e25051.	1.1	1
373	The problem of concomitant diseases with a focus on the cardiovascular system condition in patients with arterial hypertension and acid-related diseases. <i>Kazan Medical Journal</i> , 2013, 94, 80-85.	0.1	9
374	Long-term management of gastroesophageal reflux disease with pantoprazole. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 231-243.	0.9	23
375	The appropriate use of proton-pump inhibitors. <i>Minerva Medica</i> , 2018, 109, 386-399.	0.3	46
376	Heterogeneity of endoscopy negative heartburn: Epidemiology and natural history. <i>World Journal of Gastroenterology</i> , 2008, 14, 5233.	1.4	10
377	Outcome of nonerosive gastro-esophageal reflux disease patients with pathological acid exposure. <i>World Journal of Gastroenterology</i> , 2009, 15, 5700.	1.4	2
378	Revision of failed transoral incisionless fundoplication by subsequent laparoscopic Nissen fundoplication. <i>World Journal of Gastroenterology</i> , 2014, 20, 17115.	1.4	20
379	Efficacy of Drugs Used in Gastro-Oesophageal Reflux: Network Meta-Analysis. <i>Pharmacology & Pharmacy</i> , 2013, 04, 201-208.	0.2	2
380	Pre-operative clinical and instrumental factors as antireflux surgery outcome predictors. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 719.	0.8	9
381	2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease. <i>Journal of Neurogastroenterology and Motility</i> , 2021, 27, 453-481.	0.8	52

#	ARTICLE	IF	CITATIONS
382	Erkrankungen des Magen-Darm-Traktes. , 2003, , 715-861.		0
384	Medical, Surgical, and Endoscopic Management of Gastroesophageal Reflux Disease. , 2009, 13, 30-36.		2
386	Medical Therapy for Gastroesophageal Reflux Disease. , 2013, , 215-225.		0
387	Nonerosive Reflux Disease. Korean Journal of Medicine, 2015, 88, 27.	0.1	1
388	Contemporary Approaches to the Treatment of Gastroesophageal Reflux Disease. Russian Journal of Gastroenterology Hepatology Coloproctology, 2019, 29, 7-16.	0.2	4
389	Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditionsâ€”A debate: Con. Current Treatment Options in Cardiovascular Medicine, 2007, 10, 305-311.	0.4	0
392	Ã–sophaguserkrankungen. , 2005, , 677-695.		0
393	Ã–sophaguserkrankungen. , 2007, , 742-762.		0
395	Finding relief for the self-conscious esophagus: laparoscopic anti-reflux surgery and the esophageal hypersensitivity and anxiety scale. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 7656-7663.	1.3	2
396	Narrow-band imaging for the diagnosis of nonerosive refluxÃ–disease: an international, multicenter, randomized controlled trial. Gastrointestinal Endoscopy, 2022, 96, 457-466.e3.	0.5	5
397	Current advances in the diagnosis and management of gastroesophageal reflux disease. Tzu Chi Medical Journal, 2022, 34, 402.	0.4	3
401	Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. BMJ Open Gastroenterology, 2022, 9, e000941.	1.1	0
402	Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network <scp>Meta-Analysis</scp>. Neurogastroenterology and Motility, 2023, 35, .	1.6	8
404	Examination on Factors Affecting Symptom Change after Drug Withdrawal in Patients with Mild Erosive Gastroesophageal Reflux Disease Undergoing Symptom-Controlled Maintenance Therapy with Acid-Secretion Inhibition Drugs. Digestion, 2023, 104, 270-282.	1.2	0
405	Sex Differences in Gastroesophageal Reflux Disease (GERD). Foregut, 2023, 3, 192-198.	0.3	0